Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithyroid drugs. Practical conclusions.

J Leclère

    Hormone Research
    |January 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Antithyroid drug therapy for hyperthyroidism optimally lasts 18 months. Early radioiodine uptake, thyroid-stimulating antibodies, and TSH levels predict treatment success after stopping antithyroid drugs.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    2012 European thyroid association guidelines for the management of familial and persistent sporadic non-autoimmune hyperthyroidism caused by thyroid-stimulating hormone receptor germline mutations.

    European thyroid journal·2014
    Same author

    Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations.

    European journal of endocrinology·2010
    Same author

    Patient experiences and preferences: development of practice guidelines in a cancer imaging department.

    Cancer imaging : the official publication of the International Cancer Imaging Society·2009
    Same author

    Bone metastases from differentiated thyroid carcinoma.

    Endocrine-related cancer·2008
    Same author

    Imaging of chondrosarcomas.

    Cancer imaging : the official publication of the International Cancer Imaging Society·2008
    Same author

    Imaging of sacral tumours.

    Skeletal radiology·2007
    Same journal

    Abstracts of the LWPES/ESPE 8th Joint Meeting Global Care in Paediatric Endocrinology, in collaboration with APEG, APPES, JSPE and SLEP. New York City, New York, USA. September 9-12, 2009.

    Hormone research·2011
    Same journal

    Abstracts of the 47th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Istanbul, Turkey. September 20-23, 2008.

    Hormone research·2011
    Same journal

    Abstracts of the 46th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Helsinki, Finland. June 27-30, 2007.

    Hormone research·2011
    Same journal

    Genetic and pathogenetic aspects of Noonan syndrome and related disorders.

    Hormone research·2009
    Same journal

    Response to growth hormone in short children with Noonan syndrome: correlation to genotype.

    Hormone research·2009
    Same journal

    Growth hormone and the heart in Noonan syndrome.

    Hormone research·2009
    See all related articles

    Area of Science:

    • Endocrinology
    • Pharmacology

    Background:

    • Antithyroid drugs (ATD) are a cornerstone in managing hyperthyroidism.
    • Determining the optimal duration and predicting treatment outcomes remain critical clinical challenges.

    Purpose of the Study:

    • To define the optimal duration of antithyroid drug (ATD) therapy.
    • To identify key parameters for predicting treatment success following ATD withdrawal.

    Main Methods:

    • Inferred management protocols from existing literature.
    • Evaluated early radioiodine uptake and thyroid-stimulating antibodies before ATD cessation.
    • Assessed TRH stimulation tests or ultrasensitive TSH levels three months post-ATD withdrawal.

    Main Results:

    • An 18-month duration is identified as optimal for ATD treatment.

    Related Experiment Videos

  • Early radioiodine uptake and thyroid-stimulating antibodies are significant predictors of outcome.
  • Normalized TRH tests or ultrasensitive TSH levels provide additional prognostic value.

    • Conclusions:

    • A combination of early radioiodine uptake, thyroid-stimulating antibodies, and post-treatment TSH/TRH testing can guide follow-up schedules.
    • These parameters aid in predicting the likelihood of remission or relapse after ATD therapy.